Clinical Trial Update: Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of pembrolizumab in combination with mifepristone for advanced HER2-negative breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Mifepristone (mifepristone)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Chicago | Conditions: Triple Negative Breast Neoplasms, Breast Cancer | Phase 2 | Status: TERMINATED